Sign In
Buy EWTX
$43.52
-0.90 (-2.03%)
At Close: Aug 07, 2026
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
08:00am, Friday, 10'th May 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Market
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
08:00am, Tuesday, 07'th May 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arle
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted O
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
08:00am, Thursday, 28'th Mar 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the A
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
08:00am, Wednesday, 27'th Mar 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Mus
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an inv
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
10:56am, Monday, 26'th Feb 2024
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend i
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
08:00am, Tuesday, 13'th Feb 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has g
Insider Favorites: 7 Stocks with Bullish Buying Signals
02:55pm, Sunday, 11'th Feb 2024
While investors shouldn't get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it's difficult to tell what insider selling means.
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
10:56am, Friday, 09'th Feb 2024
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
01:09pm, Saturday, 27'th Jan 2024
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
10:56am, Wednesday, 24'th Jan 2024
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
03:11pm, Monday, 22'nd Jan 2024
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
08:37am, Friday, 19'th Jan 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 s
